Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain

P. Espinal, M. D. Macià, I. Roca, E. Gato, E. Ruíz, F. Fernández-Cuenca, A. Oliver, J. Rodríguez-Baño, G. Bou, M. Tomás, J. Vila
P. Espinal
aDepartment of Clinical Microbiology, School of Medicine, IDIBAPS and Barcelona Centre for International Health Research, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. D. Macià
bHospital Son Espases, Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Roca
aDepartment of Clinical Microbiology, School of Medicine, IDIBAPS and Barcelona Centre for International Health Research, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Gato
cCHU a Coruña—INIBIC, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Ruíz
bHospital Son Espases, Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Fernández-Cuenca
dHospital Virgen Macarena, Seville, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Oliver
bHospital Son Espases, Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Rodríguez-Baño
dHospital Virgen Macarena, Seville, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Bou
cCHU a Coruña—INIBIC, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Tomás
cCHU a Coruña—INIBIC, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Vila
aDepartment of Clinical Microbiology, School of Medicine, IDIBAPS and Barcelona Centre for International Health Research, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01157-12
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A carbapenem-resistant Acinetobacter baumannii clinical isolate belonging to European clone II and sequence type 2 was recovered from a patient in the Son Espases hospital in Mallorca, Spain. Genetic analysis showed the presence of the blaOXA-23 gene in association with the widely disseminated transposon Tn2006. This is the first reported identification of A. baumannii carrying blaOXA-23 in Spain.

TEXT

Acinetobacter baumannii is responsible for hospital outbreaks, and it is considered one of the most important nosocomial pathogens causing bacteremia, pneumonia, and other respiratory and urinary tract infections (1, 2). The abilities to acquire resistance mechanisms and to persist in the environment for long periods of time make this pathogen difficult to eradicate from the clinical setting (3, 4). The resistance of A. baumannii isolates to carbapenems is on the rise mainly in association with a variety of combined mechanisms, among which the production of acquired carbapenem-hydrolyzing OXA-type class D β-lactamases (CHDLs), OXA-23 in particular, has been identified worldwide (2).

Here we report the first case of OXA-23 in an A. baumannii clinical isolate in Spain and in association with the widely spread Tn2006 transposon.

OXA-23 was identified in a clinical isolate from a 59-year-old male patient admitted to the Department of Pneumology at the Son Espases hospital in Mallorca, Spain, in February 2010 because of increased dyspnea, coughing, chills, and purulent secretions during the previous 3 days. The patient was born in Portugal and had lived in Palma de Mallorca since 1998, although he had traveled to Portugal and France during the previous year. The patient had been hospitalized in Lisbon between 7 and 23 December 2009 and then again in another hospital between 26 December 2009 and 8 January 2010. He was a former smoker and had needed multiple hospital admissions because of exacerbations of chronic obstructive pulmonary disease. His regular medication included bronchodilators but no antibiotics. On the second day after admission, A. baumannii was isolated from his sputum and the patient was empirically treated with levofloxacin (500 to 750 mg/day) but switched to intravenous colistin (2 to 3 MU/8 h) after 6 days because of susceptibility test results. The patient improved and was discharged for specialized home care. After the initial isolation, periodic sputum cultures were taken for several months with no further isolation of the strain.

A. baumannii isolate AB 308 was initially identified by MicroScan and confirmed by matrix-assisted laser desorption ionization–time of flight mass spectrometry (Bruker Daltonics GmbH, Leipzig, Germany). Antibiotic susceptibilities were determined by MicroScan (Siemens) for most antimicrobial agents, except colistin and tigecycline, which were determined by Etest (AB bioMérieux, Solna, Sweden). These results were interpreted according to CLSI guidelines (5). The AB 308 isolate was resistant to amikacin (>256 μg/ml), ceftazidime (>128 μg/ml), tetracycline, ciprofloxacin, gentamicin, netilmicin (>64 μg/ml), piperacillin (>512 μg/ml), imipenem, and meropenem (>16 μg/ml). The MIC of both tigecycline and colistin was 0.5 μg/ml.

PCR detection of metallo-beta-lactamase and CHDL genes (6–8) was only positive for blaOXA-51 and blaOXA-23. The insertion sequence ISAba1was found upstream of blaOXA-23 but not upstream of blaOXA-51.

The genetic location of blaOXA-23 was determined by S1 nuclease pulsed-field gel electrophoresis (PFGE) and Southern blot analysis with a digoxigenin-labeled probe (Roche, Barcelona, Spain) matching the blaOXA-23 gene. S1 PFGE revealed a band of ca. 100 kb with no signal hybridization with the probe. However, we detected a positive signal matching the bacterial chromosome indicating the chromosomal location of blaOXA-23 (Fig. 1).

Fig 1
  • Open in new tab
  • Download powerpoint
Fig 1

Southern blot assay. Lane a, PFGE analysis of the AB 308 strain by digestion with S1 nuclease. Lane b, hybridization with a blaOXA-23 probe. The black arrow indicates the chromosomal location with positive hybridization with the blaOXA-23 probe. The white arrow indicates a plasmid band with no hybridization with the probe. Lanes M, lambda ladder PFGE marker (New England BioLabs).

Characterization of the genetic structures surrounding the blaOXA-23 gene was performed by inverse PCR (9) with primers OXA23invF (5′-GGAAAGACTGGTTGGGCAATGG-3′) and OXA-23invR (5′-CACCTCAGGTGTGCTGGTTATTC-3′) and revealed genetic structures neighboring the blaOXA-23 gene consistent with the arrangement of the previously described composite transposon Tn2006 (10, 11).

AB 308 was included within European clone II (EC-II) (12), and multilocus sequence typing performed according to the scheme devised by Nemec et al. (13) allowed the allocation of the AB 308 strain to sequence type 2 (ST2) (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html).

In this report, we describe the first identification of an A. baumannii clinical isolate carrying blaOXA-23 associated with Tn2006 in Spain. Until recently, A. baumannii isolates bearing CHDLs in Spain were related mainly to OXA-24 (14, 15). Interestingly, the emergence and spread of several outbreak or sporadic A. baumannii strains producing OXA-23 related to EC-II and ST2 have been reported around the world (4, 11, 16–18).

Moreover, in countries in the Mediterranean region, there seems to be a trend toward the replacement of OXA-58/OXA-24-producing A. baumannii by OXA-23 producers, also associated with A. baumannii strains belonging to EC-II and ST2 and carrying Tn2006. In central Italy, an interesting replacement of blaOXA-58 with blaOXA-23 belonging to EC-II has recently been established (18, 19) and a similar abrupt shift has also been reported in Greece and Algeria, where 72.4% and 92% of the carbapenem-resistant isolates tested harbored the blaOXA-23 gene (20, 21), while the blaOXA-58 gene was predominant in those countries half a decade ago. All of the blaOXA-23 genes from Italy and Greece were located within Tn2006 transposons, either chromosomally or in plasmids.

In Portugal, carbapenem-resistant A. baumannii isolates have typically been associated with OXA-24 but a predominance of blaOXA-23 (63%) has been detected since 2006. All of the isolates belonged to EC-II and ST2 and carried Tn2006 chromosomally (17). While the replacement of OXA-58 by OXA-23 might be explained by the selective advantage associated with the higher carbapenemase activity of OXA-23, the selective advantage of OXA-23 over OXA-24 producers is not clear but could be linked to additional features within the carrying clone (i.e., extensive multidrug resistance), which might explain why OXA-23 in Italy and Greece is associated with epidemiologically diverse clones carrying either chromosomal or plasmidic blaOXA-23, while in Portugal, OXA-23 dissemination is caused by a particular clone (17).

The AB 308 strain described in this study, however, was not related to any outbreak in Spain and represented the only OXA-23-producing A. baumannii strain out of 456 Acinetobacter strains collected in a nationwide multicenter study in Spain performed during 2010. Therefore, it is not likely that OXA-23 producers were disseminating throughout Spain in 2010 and AB 308 was probably acquired during a recent trip to either France or Portugal. Nevertheless, recent investigations have reported two OXA-23 outbreaks in Spain in 2012 (J. Vila and G. Bou, personal communication); therefore, in the years to come, we might expect an eruption of A. baumannii strains carrying OXA-23 in this country as well.

The genomic plasticity of the strains carrying blaOXA-23 associated with the composite transposon Tn2006 allows mobilization or transposition events to occur more easily, since insertions can occur in different locations on the chromosome or even in plasmids, and the emerging spread of carbapenem-resistant A. baumannii strains associated with transposon structures and the worldwide dissemination of EC-II and ST2 represent a worrying threat, as well as an important challenge for surveillance and infection control measures.

ACKNOWLEDGMENTS

This study was supported by the Spanish Ministry of Health (FIS PI10/00056) and by the Instituto de Salud Carlos III-FEDER, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008). This work was also supported by funding from the European Community (TROCAR contract HEALTH-F3-2008-223031). M. Tomás was financially supported by the Miguel Servet Program (CHU a Coruña and ISCIII).

FOOTNOTES

    • Received 1 June 2012.
    • Returned for modification 30 July 2012.
    • Accepted 7 October 2012.
    • Accepted manuscript posted online 15 October 2012.
  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Antunes LC,
    2. Imperi F,
    3. Carattoli A,
    4. Visca P
    . 2011. Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity. PLoS One 6:e22674. doi:10.1371/journal.pone.0022674.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Roca I,
    2. Espinal P,
    3. Vila-Farres X,
    4. Vila J
    . 2012. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front. Microbiol. 3:148.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Espinal P,
    2. Marti S,
    3. Vila J
    . 2012. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 80:56–60.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kohlenberg A,
    2. Brummer S,
    3. Higgins PG,
    4. Sohr D,
    5. Piening BC,
    6. de Grahl C,
    7. Halle E,
    8. Ruden H,
    9. Seifert H
    . 2009. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J. Med. Microbiol. 58:1499–1507.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    CLSI. 2011. Performance standards for antimicrobial susceptibility testing, 15th informational supplement, M100-515. Clinical and Laboratory Standards Institute, Wayne, PA.
  6. 6.↵
    1. Ellington MJ,
    2. Kistler J,
    3. Livermore DM,
    4. Woodford N
    . 2007. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J. Antimicrob. Chemother. 59:321–322.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Poirel L,
    2. Walsh TR,
    3. Cuvillier V,
    4. Nordmann P
    . 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70:119–123.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Woodford N,
    2. Ellington MJ,
    3. Coelho JM,
    4. Turton JF,
    5. Ward ME,
    6. Brown S,
    7. Amyes SG,
    8. Livermore DM
    . 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351–353.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Espinal P,
    2. Fugazza G,
    3. López Y,
    4. Kasma M,
    5. Lerman Y,
    6. Malhotra-Kumar S,
    7. Goossens H,
    8. Carmeli Y,
    9. Vila J
    . 2011. Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center. Antimicrob. Agents Chemother. 55:5396–5398.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Corvec S,
    2. Poirel L,
    3. Naas T,
    4. Drugeon H,
    5. Nordmann P
    . 2007. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:1530–1533.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Mugnier PD,
    2. Poirel L,
    3. Naas T,
    4. Nordmann P
    . 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg. Infect. Dis. 16:35–40.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Turton JF,
    2. Gabriel SN,
    3. Valderrey C,
    4. Kaufmann ME,
    5. Pitt TL
    . 2007. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin. Microbiol. Infect. 13:807–815.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Nemec A,
    2. Krizova L,
    3. Maixnerova M,
    4. Diancourt L,
    5. van der Reijden TJ,
    6. Brisse S,
    7. van den Broek P,
    8. Dijkshoorn L
    . 2008. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J. Antimicrob. Chemother. 62:484–489.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Bou G,
    2. Oliver A,
    3. Martinez-Beltrán J
    . 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 44:1556–1561.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ruiz M,
    2. Marti S,
    3. Fernandez-Cuenca F,
    4. Pascual A,
    5. Vila J
    . 2007. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin. Microbiol. Infect. 13:1192–1198.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Grosso F,
    2. Carvalho KR,
    3. Quinteira S,
    4. Ramos A,
    5. Carvalho-Assef AP,
    6. Asensi MD,
    7. Peixe L
    . 2011. OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro? J. Antimicrob. Chemother. 66:62–65.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Grosso F,
    2. Quinteira S,
    3. Peixe L
    . 2011. Understanding the dynamics of imipenem-resistant Acinetobacter baumannii lineages within Portugal. Clin. Microbiol. Infect. 17:1275–1279.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Minandri F,
    2. D'Arezzo S,
    3. Antunes LC,
    4. Pourcel C,
    5. Principe L,
    6. Petrosillo N,
    7. Visca P
    . 2012. Evidence of diversity among epidemiologically related carbapenemase-producing Acinetobacter baumannii strains belonging to international clonal lineage II. J. Clin. Microbiol. 50:590–597.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. D'Arezzo S,
    2. Principe L,
    3. Capone A,
    4. Petrosillo N,
    5. Petrucca A,
    6. Visca P
    . 2011. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J. Antimicrob. Chemother. 66:54–61.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Liakopoulos A,
    2. Miriagou V,
    3. Katsifas EA,
    4. Karagouni AD,
    5. Daikos GL,
    6. Tzouvelekis LS,
    7. Petinaki E
    . 2012. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill. 17(11):20117.
    OpenUrlPubMed
  21. 21.↵
    1. Touati M,
    2. Diene SM,
    3. Racherache A,
    4. Dekhil M,
    5. Djahoudi A,
    6. Rolain JM
    . 2012. Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria. Int. J. Antimicrob. Agents 40:89–91.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain
P. Espinal, M. D. Macià, I. Roca, E. Gato, E. Ruíz, F. Fernández-Cuenca, A. Oliver, J. Rodríguez-Baño, G. Bou, M. Tomás, J. Vila
Antimicrobial Agents and Chemotherapy Dec 2012, 57 (1) 589-591; DOI: 10.1128/AAC.01157-12

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006 in Spain
P. Espinal, M. D. Macià, I. Roca, E. Gato, E. Ruíz, F. Fernández-Cuenca, A. Oliver, J. Rodríguez-Baño, G. Bou, M. Tomás, J. Vila
Antimicrobial Agents and Chemotherapy Dec 2012, 57 (1) 589-591; DOI: 10.1128/AAC.01157-12
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596